New Advances in Lung Cancer: Diagnosis, Pathophysiology and Emerging Treatments. A Selection of Papers from the 4th Joint Meeting on Lung Cancer of the FHU OncoAge (Nice, France) and the MD Anderson Cancer Center (Houston, TX, USA)

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 31 July 2024 | Viewed by 504

Special Issue Editors


E-Mail Website
Guest Editor
Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Interests: thoracic oncology

Special Issue Information

Dear Colleagues,

Lung cancer has become a paradigm for personalized medicine, where identifying disease subtypes through oncogenic driver mutations has led to the development of molecularly targeted therapies. Moreover, the impact of driver oncogenes on the immune tumor microenvironment has profound implications for the effectiveness of immune checkpoint inhibitors. In this regard, there is an urgent need to address obstacles hindering clinical advancements in I-O and targeted therapies, including the development of accurate preclinical models mimicking human immunity and understanding molecular and cellular determinants of primary and secondary resistance. The design of effective combinations of personalized therapies is crucial for individual patient treatment. New treatments such as antibody–drug conjugates (ADCs) could be used in the near future in lung cancer patients, alone or in combination with other therapeutic strategies. These new treatments should be associated with the development of predictive biomarkers. This Special Issue of Cancers focuses on recent topics of interest associated with lung cancer. This follows the 4th joint meeting between different physicians and researchers from both the MD Anderson Cancer Center (Houston, TX, USA), the FHU OncoAge (Nice, France), and the IHU RespirERA (Nice, France). The main objective of this Special Issue is to promote the recent understanding of the development of lung cancer, including new therapeutic strategies and new biomarkers.

Prof. Dr. Paul Hofman
Dr. Ignacio I. Wistuba
Dr. John Heymach
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lung cancer
  • predictive biomarkers
  • liquid biopsy
  • targeted therapy
  • immunotherapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 1839 KiB  
Article
Shifting from Immunohistochemistry to Screen for ALK Rearrangements: Real-World Experience in a Large Single-Center Cohort of Patients with Non-Small-Cell Lung Cancer
by Marius Ilié, Samantha Goffinet, Guylène Rignol, Virginie Lespinet-Fabre, Salomé Lalvée, Olivier Bordone, Katia Zahaf, Christelle Bonnetaud, Kevin Washetine, Sandra Lassalle, Elodie Long-Mira, Simon Heeke, Véronique Hofman and Paul Hofman
Cancers 2024, 16(12), 2219; https://doi.org/10.3390/cancers16122219 - 14 Jun 2024
Viewed by 276
Abstract
The identification of ALK fusions in advanced non-small-cell lung carcinoma (aNSCLC) is mandatory for targeted therapy. The current diagnostic approach employs an algorithm using ALK immunohistochemistry (IHC) screening, followed by confirmation through ALK FISH and/or next-generation sequencing (NGS). Challenges arise due to the [...] Read more.
The identification of ALK fusions in advanced non-small-cell lung carcinoma (aNSCLC) is mandatory for targeted therapy. The current diagnostic approach employs an algorithm using ALK immunohistochemistry (IHC) screening, followed by confirmation through ALK FISH and/or next-generation sequencing (NGS). Challenges arise due to the infrequency of ALK fusions (3–7% of aNSCLC), the suboptimal specificity of ALK IHC and ALK FISH, and the growing molecular demands placed on small tissue samples, leading to interpretative, tissue availability, and time-related issues. This study investigates the effectiveness of RNA NGS as a reflex test for identifying ALK fusions in NSCLC, with the goal of replacing ALK IHC in the systematic screening process. The evaluation included 1246 NSCLC cases using paired techniques: ALK IHC, ALK FISH, and ALK NGS. ALK IHC identified 51 positive cases (4%), while RNA NGS detected ALK alterations in 59 cases (4.8%). Of the 59 ALK-positive cases identified via NGS, 53 (89.8%) were confirmed to be positive. This included 51 cases detected via both FISH and IHC, and 2 cases detected only via FISH, as they were completely negative according to IHC. The combined reporting time for ALK IHC and ALK FISH averaged 13 days, whereas ALK IHC and RNA NGS reports were obtained in an average of 4 days. These results emphasize the advantage of replacing systematic ALK IHC screening with RNA NGS reflex testing for a more comprehensive and accurate assessment of ALK status. Full article
Show Figures

Figure 1

Back to TopTop